Stapled Peptide Inhibiting BIG3-PHB2 Interaction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current dominant negative peptides used to inhibit the BIG3-PHB2 interaction in breast cancer therapy have low stability and short-lasting inhibitory effects, necessitating the development of peptides with longer-lasting inhibitory actions.
Innovation Solution
Introduction of stapling structures into the dominant negative peptide molecule, specifically substituting amino acid residues with stapling structures at defined positions in the peptide sequence, to enhance stability and duration of action.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a dominant negative peptide is used to inhibit the BIG3-PHB2 interaction, then the tumor suppressive activity of PHB2 is reactivated, but the stability and duration of inhibitory effects are insufficient
Solution Approach 1:
The patent applies parameter changes by modifying the peptide's structural parameters - specifically introducing stapling structures (crosslinks between amino acid residues) to alter the peptide's conformational stability, hydrophobicity, and resistance to proteolytic degradation, thereby extending its duration of action and improving inhibitory effect stability
Solution Approach 2:
The patent creates a composite peptide structure by combining the dominant negative peptide sequence with stapling structures (such as olefin crosslinks or other stabilizing moieties), forming a hybrid molecule that integrates the functional properties of the original peptide with the stabilizing properties of the stapling structures, resulting in enhanced reliability and duration of action
Data Source
AI summary
The present invention provides peptides containing a structure in which a portion of the dominant negative peptide of BIG3 which inhibits the interaction between BIG3 and PHB2 is substituted with stapling structure(s). Peptides of the present invention have excellent cell growth inhibitory actions. Furthermore, their cell growth inhibitory actions continue for a longer time than the actions of peptides without stapling structures. Therefore, these peptides have features suitable for clinical applications in cancer therapy.